Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Two men claim they developed bone and kidney problems after taking TDF. A related class action lawsuit has also been filed.
An analysis of a previous study of a tenofovir-based vaginal gel found that women with vaginal inflammation were less protected.
Largest-ever analysis of bone loss in the HIV population found that treating hep C, taking vitamin D and exercising might be preventive.
New trial compares Descovy to Truvada.
The AIDS Healthcare Foundation alleges Gilead could have developed the safer version of tenofovir earlier.
Increases may be designed to push patients to the company’s newer regimens.
The FDA has approved the single-tablet antiretroviral regimen Odefsey, which includes a new, safer version of tenofovir.
The FDA has approved Gilead Science’s Genvoya, which is the first HIV treatment to include an updated version of tenofovir.
Among people who fail HIV treatment, resistance to tenofovir is common, and the incidence of such acquired resistance is likely increasing.
Lawsuit: Gilead has manipulated the patent system to extend its control (and profit) of tenofovir, found in many HIV regimens.
Long-term Viread (tenofovir disoproxil fumarate, or TDF) use is linked with a raised risk of end-stage liver cancer in HIV-positive people.
The HIV drug TAF, a new, safer version of Viread (TDF), offers premium benefits.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.